港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张公允价值变动有望贡献利润

智通财经2025-12-23

智通财经APP获悉，昭衍新药(06127)涨超5%，截至发稿，涨5.17%，报22.38港元，成交额1.16亿港元。消息面上，国海证券12月22日研报指出，临床前CRO客户需求回暖，上游实验猴供给端紧张。安评阶段，大分子（多抗、ADC）、小核酸、多肽、细胞基因疗法等新技术平台均需要食蟹猴模拟人体进行安评试验检测药物安全性数据，目前3-5岁左右是食蟹猴已涨到14万元一只，年内已出现供不应求的局面，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593945005?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-23 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593945005","market":"fut","top_or_hot":-1,"title":"港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张 公允价值变动有望贡献利润","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，昭衍新药(06127)涨超5%，截至发稿，涨5.17%，报22.38港元，成交额1.16亿港元。消息面上，国海证券12月22日研报指出，临床前CRO客户需求回暖，上游实验猴供给端紧张。安评阶段，大分子（多抗、ADC）、小核酸、多肽、细胞基因疗法等新技术平台均需要食蟹猴模拟人体进行安评试验检测药物安全性数据，目前3-5岁左右是食蟹猴已涨到14万元一只，年内已出现供不应求的局面，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1384769.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张 公允价值变动有望贡献利润</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张 公允价值变动有望贡献利润\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 10:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1384769.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，昭衍新药(06127)涨超5%，截至发稿，涨5.17%，报22.38港元，成交额1.16亿港元。消息面上，国海证券12月22日研报指出，临床前CRO客户需求回暖，上游实验猴供给端紧张。安评阶段，大分子（多抗、ADC）、小核酸、多肽、细胞基因疗法等新技术平台均需要食蟹猴模拟人体进行安评试验检测药物安全性数据，目前3-5岁左右是食蟹猴已涨到14万元一只，年内已出现供不应求的局面，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1384769.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603127","symbol_name":"昭衍新药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1384769.html","article_id":"2593945005","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593945005","pubTimestamp":1766457795,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，昭衍新药涨超5%，截至发稿，涨5.17%，报22.38港元，成交额1.16亿港元。消息面上，国海证券12月22日研报指出，临床前CRO客户需求回暖，上游实验猴供给端紧张。据方正证券测算，以昭衍新药为例，假设按照2024年实验猴均价计入公允价值8.49万/只，2025Q4价格提升至14万/只，假设猴场出栏率为17%，按照已知23200只猴测算，毛估计2025年新增公允价值约2.2亿。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603127":"昭衍新药","06127":"昭衍新药","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK0216":"研究试验"},"translate_title":"Changes in Hong Kong stocks | Zhaoyan New Drug (06127) rose more than 5%. The supply side of upstream experimental monkeys is tight. Changes in fair value are expected to contribute to profits","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603127":1.5,"06127":1.5},"content_text":"智通财经APP获悉，昭衍新药(06127)涨超5%，截至发稿，涨5.17%，报22.38港元，成交额1.16亿港元。消息面上，国海证券12月22日研报指出，临床前CRO客户需求回暖，上游实验猴供给端紧张。安评阶段，大分子（多抗、ADC）、小核酸、多肽、细胞基因疗法等新技术平台均需要食蟹猴模拟人体进行安评试验检测药物安全性数据，目前3-5岁左右是食蟹猴已涨到14万元一只，年内已出现供不应求的局面，进一步佐证国内创新药研发景气度恢复，并且猴价上涨带来的公允价值变动也会直接贡献利润。据方正证券测算，以昭衍新药为例，假设按照2024年实验猴均价计入公允价值8.49万/只，2025Q4价格提升至14万/只，假设猴场出栏率为17%，按照已知23200只猴测算，毛估计（不考虑新补进猴子及未成年&老龄猴的影响）2025年新增公允价值约2.2亿。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593945005","isCrawlerRequest":true}

港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张 公允价值变动有望贡献利润

精彩评论

港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张公允价值变动有望贡献利润